| 71.75 0.37 (0.52%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 85.68 | 1-year : | 90.19 |
| Resists | First : | 73.35 | Second : | 77.22 |
| Pivot price | 73.9  |
|||
| Supports | First : | 67.11 | Second : | 55.83 |
| MAs | MA(5) : | 72.79 |
MA(20) : | 74.09 |
| MA(100) : | 72.4 |
MA(250) : | 62.95  |
|
| MACD | MACD : | 0.4 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 24.5 |
D(3) : | 35.8 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 109 | Low : | 31.85 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NKTR ] has closed above bottom band by 12.3%. Bollinger Bands are 63.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 72.82 - 73.23 | 73.23 - 73.61 |
| Low: | 69.34 - 69.87 | 69.87 - 70.36 |
| Close: | 70.98 - 71.75 | 71.75 - 72.46 |
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Mon, 31 Aug 2026
Peer‑Reviewed REZOLVE‑AD Phase 2b Data Could Be A Game Changer For Nektar Therapeutics (NKTR) - simplywall.st
Sun, 30 Aug 2026
NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts - stocktwits.com
Sat, 29 Aug 2026
Is Nektar Therapeutics (NKTR) Undervalued As Lancet Data Supports Its Phase 3 Path? - simplywall.st
Fri, 28 Aug 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Thu, 27 Aug 2026
Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test - Yahoo Finance
Sun, 16 Aug 2026
Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 106.1 (%) |
| Shares Short | 6,300 (K) |
| Shares Short P.Month | 6,900 (K) |
| EPS | -6.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 26.45 |
| Profit Margin | -287.9 % |
| Operating Margin | -412.3 % |
| Return on Assets (ttm) | -12.6 % |
| Return on Equity (ttm) | -35.8 % |
| Qtrly Rev. Growth | -9.4 % |
| Gross Profit (p.s.) | 1.59 |
| Sales Per Share | 1.59 |
| EBITDA (p.s.) | -3.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -234 (M) |
| Levered Free Cash Flow | -135 (M) |
| PE Ratio | -11.73 |
| PEG Ratio | 0.3 |
| Price to Book value | 2.71 |
| Price to Sales | 44.87 |
| Price to Cash Flow | -10.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|